PREVELENCEOF MULTI DRUG RESISTANTMICROBESIN COMMUNITY ACQUIREDPNEUMONIA VERSUSU HOSPITAL ACQUIRED PNEUMONIAIN PEDIATRIC CARDIAC PATIENTS
Maher Hamed, B., khalil, A., Elhewala, A., Bahgat, M. (2022). PREVELENCEOF MULTI DRUG RESISTANTMICROBESIN COMMUNITY ACQUIREDPNEUMONIA VERSUSU HOSPITAL ACQUIRED PNEUMONIAIN PEDIATRIC CARDIAC PATIENTS. EKB Journal Management System, 28(3), 479-488. doi: 10.21608/zumj.2019.17780.1573
Basma Atia Maher Hamed; azaa ali khalil; Ahmed Elhewala; Manal Abdeltawab Bahgat. "PREVELENCEOF MULTI DRUG RESISTANTMICROBESIN COMMUNITY ACQUIREDPNEUMONIA VERSUSU HOSPITAL ACQUIRED PNEUMONIAIN PEDIATRIC CARDIAC PATIENTS". EKB Journal Management System, 28, 3, 2022, 479-488. doi: 10.21608/zumj.2019.17780.1573
Maher Hamed, B., khalil, A., Elhewala, A., Bahgat, M. (2022). 'PREVELENCEOF MULTI DRUG RESISTANTMICROBESIN COMMUNITY ACQUIREDPNEUMONIA VERSUSU HOSPITAL ACQUIRED PNEUMONIAIN PEDIATRIC CARDIAC PATIENTS', EKB Journal Management System, 28(3), pp. 479-488. doi: 10.21608/zumj.2019.17780.1573
Maher Hamed, B., khalil, A., Elhewala, A., Bahgat, M. PREVELENCEOF MULTI DRUG RESISTANTMICROBESIN COMMUNITY ACQUIREDPNEUMONIA VERSUSU HOSPITAL ACQUIRED PNEUMONIAIN PEDIATRIC CARDIAC PATIENTS. EKB Journal Management System, 2022; 28(3): 479-488. doi: 10.21608/zumj.2019.17780.1573

PREVELENCEOF MULTI DRUG RESISTANTMICROBESIN COMMUNITY ACQUIREDPNEUMONIA VERSUSU HOSPITAL ACQUIRED PNEUMONIAIN PEDIATRIC CARDIAC PATIENTS

Zagazig University Medical Journal
Article 12, Volume 28, Issue 3, May 2022, Page 479-488  XML PDF (539.86 K)
Document Type: Original Article
DOI: 10.21608/zumj.2019.17780.1573
View on SCiNiTO View on SCiNiTO
Authors
Basma Atia Maher Hamed email 1; azaa ali khalil2; Ahmed Elhewala3; Manal Abdeltawab Bahgat4
1Pediatrics faculty of medicine zagazig university zagazig Egypt
2Department of Pediatric,Faculty of Medicine –ZagazigUniversity,Egypt.
3pediatric department,faculty of medicine,zagazig university,egypt
4Microbiology Department,Faculty Of Medicine,Zagazig University,Egypt
Abstract
Background: Pneumonia remains the leading infectious cause of death among children. Most cases are less than 2 years old. Around 8,388 Egyptian children died every year due to pneumonia in the past 5 years.
Objectives:Our study aimed at identifying the prevalence of multi drug resistant microbes in CAP versus HAP in paediatric cardiac patients. Patients and Methods:The present cross-sectional study was conducted at Cardiology, Chest and ICU units of PediatricZagazig University Hospital; Faculty of Medicine, Egypt during a period of six months from 1/1/2019 to 30/6/2019. 84 cardiac patients included in our study, classified into two groups: Group A: 73 cardiac patients admitted with bacterial CAP. Group B: 11 cardiac patients developed HAP after admission.
Results: Klebsiella p. was mostly sensitive to Colistin and Amikacin. E. Coli was mostly sensitive to Amikacin, Tobramycin and Tigecycline. Pseudomonas A. was mostly sensitive to Colistin and aminoglycosides. Acinetobacter B. was mostly sensitive to Amikacin, Minocycline, colistin and RD. Streptococcus P. was mostly sensitive to Vancomycin the penicillin and Amikacin. Among the 73 cases of CAP group, 65(89%) improved and 8(11%) died.
Conclusion: Resistance of pathogens of LRTI to different antibiotics has increased with emergence of high percentage of multi-drug resistant strains. Amikacin, Colistin (not used in pediatrics), Tigecycline and Linezolid proved to be the most potent antibiotics against most of CAP and HAP pneumonia, but restriction of their use is important to prevent emergence of resistant strains.
Keywords: Klebsiella pneumonia ,Community Acquired Pneumonia,Hospital Acquired pneumonia
Keywords
Klebsiella pneumonia; Community Acquired Pneumonia; Hospital Acquired pneumonia
Statistics
Article View: 265
PDF Download: 144